Online citations, reference lists, and bibliographies.
Referencing for people who value simplicity, privacy, and speed.
Get Citationsy
← Back to Search

Biochemical Recurrence After Radical Prostatectomy With Or Without Pelvic Lymphadenectomy In Korean Men With High-risk Prostate Cancer.

J. Ku, C. Jeong, Y. Park, M. Cho, C. Kwak, H. Kim
Published 2011 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy Visualize in Litmaps
Share
Reduce the time it takes to create your bibliography by a factor of 10 by using the world’s favourite reference manager
Time to take this seriously.
Get Citationsy
OBJECTIVE To identify predictors of biochemical recurrence (BCR) after radical prostatectomy with or without standard pelvic lymphadenectomy in Korean men with high-risk prostate cancer. METHODS The clinical and pathologic data of 199 patients with high-risk features were reviewed retrospectively. High-risk features were prostate-specific antigen level >20 ng/ml, biopsy Gleason score ≥8 or clinical tumor category ≥2c. All patients were followed up by measuring their prostate-specific antigen levels every 3 months. The median follow-up period was 37.0 months (range: 1.0-143.0). RESULTS During the follow-up period, biochemical recurrence was observed in 68 patients (34.2%). The 1-, 3- and 5-year biochemical recurrence-free survival rates were 79.6, 61.9 and 49.2%, respectively. Surgical Gleason score ≥8, positive surgical margin, extracapsular extension, and seminal vesicle invasion correlated significantly with biochemical recurrence-free survival (all P < 0.05), but pelvic lymphadenectomy did not. Multivariate Cox's proportional hazard analysis revealed that the only significant independent prognostic factor of biochemical recurrence-free survival was seminal vesicle invasion (P = 0.035, relative risk = 1.81). CONCLUSIONS Men with seminal vesicle invasion appear to have a significantly higher biochemical recurrence risk in patients with high-risk prostate cancer. However, since the natural history of prostate cancer is variable and accurate means of identifying those who will progress are currently available, it will be necessary to conduct further studies to find prognostic parameters that will allow the early identification of high-risk patients who could benefit from early salvage or adjuvant therapy.
This paper references
Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer.
J. Kirkpatrick (1998)
10.1016/J.EURURO.2005.10.012
Postoperative Radiotherapy After Radical Prostatectomy: A Randomised Controlled Trial (EORTC trial 22911)
R. Ackermann (2006)
10.3346/jkms.2005.20.2.262
Nomograms for the Prediction of Pathologic Stage of Clinically Localized Prostate Cancer in Korean Men
Cheryn Song (2005)
10.1016/S0022-5347(05)00388-5
Risk of prostate cancer-specific mortality following biochemical recurrence after radical prostatectomy.
S. Freedland (2005)
10.1016/S0360-3016(96)00513-5
Beneficial effect of combination hormonal therapy administered prior and following external beam radiation therapy in localized prostate cancer.
J. Laverdière (1997)
10.1001/JAMA.1997.03540420041027
Combination of prostate-specific antigen, clinical stage, and Gleason score to predict pathological stage of localized prostate cancer. A multi-institutional update.
A. Partin (1997)
10.1097/01.JU.0000154610.81916.81
Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE).
M. Meng (2005)
10.1097/01.JU.0000155533.93528.4C
The extent of lymphadenectomy for pTXNO prostate cancer does not affect prostate cancer outcome in the prostate specific antigen era.
D. S. Dimarco (2005)
10.1016/J.UROLONC.2006.05.001
Patients at high risk of progression after radical prostatectomy: Do they all benefit from immediate post-operative irradiation? (EORTC trial 22911)
M. Ritter (2006)
10.1016/J.UROLOGY.2006.01.055
Impact of extent of lymphadenectomy on survival after radical prostatectomy for prostate cancer.
S. Joslyn (2006)
10.1001/JAMA.281.17.1591
Natural history of progression after PSA elevation following radical prostatectomy.
C. Pound (1999)
10.1016/J.EJCA.2005.06.024
Patients at high risk of progression after radical prostatectomy: do they all benefit from immediate post-operative irradiation? (EORTC trial 22911).
L. Collette (2005)
10.1016/J.JURO.2006.03.093
Long-term outcome following radical prostatectomy in men with clinical stage T3 prostate cancer.
B. Carver (2006)
10.1016/J.UROLOGY.2006.04.029
Prostate cancer in Korean men exhibits poor differentiation and is adversely related to prognosis after radical prostatectomy.
Cheryn Song (2006)
10.1111/j.1464-410X.2005.05394.x
Radical prostatectomy for clinically advanced (cT3) prostate cancer since the advent of prostate‐specific antigen testing: 15‐year outcome
J. Ward (2005)
10.1016/S0360-3016(01)01579-6
Phase III radiation therapy oncology group (RTOG) trial 86-10 of androgen deprivation adjuvant to definitive radiotherapy in locally advanced carcinoma of the prostate.
M. Pilepich (2001)
10.1016/J.UROLONC.2004.08.003
Salvage radiotherapy for recurrent prostate cancer after radical prostatectomy
P. Carroll (2004)
10.1016/S0360-3016(96)00590-1
Stage T1-2 prostate cancer: a multivariate analysis of factors affecting biochemical and clinical failures after radical prostatectomy.
P. Kupelian (1997)
10.1200/JCO.2002.01.086
Radical radiation for localized prostate cancer: local persistence of disease results in a late wave of metastases.
J. Coen (2002)
Jpn J Clin Oncol
(2011)
10.1016/S0022-5347(17)35410-1
The use of prostate specific antigen, clinical stage and Gleason score to predict pathological stage in men with localized prostate cancer.
A. Partin (1993)
10.1200/JCO.2005.08.904
Identifying patients at risk for significant versus clinically insignificant postoperative prostate-specific antigen failure.
A. D'Amico (2005)
10.1016/S0022-5347(01)65967-6
Analysis of risk factors for progression in patients with pathologically confined prostate cancers after radical retropubic prostatectomy.
S. E. Lerner (1996)
10.1016/J.JURO.2006.06.069
Metastatic prostate cancer-does treatment of the primary tumor matter?
G. Swanson (2006)
10.1200/JCO.1999.17.5.1499
Postoperative nomogram for disease recurrence after radical prostatectomy for prostate cancer.
M. Kattan (1999)
10.1016/J.UROLOGY.2005.12.003
Radical prostatectomy as primary treatment modality for locally advanced prostate cancer: a prospective analysis.
R. Berglund (2006)
10.1016/J.UROLOGY.2006.10.031
Role of pelvic lymphadenectomy in prostate cancer management.
S. Sivalingam (2007)
10.1016/J.EURURO.2006.08.050
Is radical prostatectomy feasible in all cases of locally advanced non-bone metastatic prostate cancer? Results of a single-institution study.
P. Gontero (2007)
10.1016/S0140-6736(05)67101-2
Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911)
M. Bolla (2005)



This paper is referenced by
10.7150/JCA.29714
Prostate specific antigen (PSA) persistence 6 weeks after radical prostatectomy and pelvic lymph node dissection as predictive factor of radiographic progression in node-positive prostate cancer patients
J. Kim (2019)
What is the High Risk Prostate Cancer
S. Park (2012)
10.1016/j.urolonc.2012.11.021
The presence of positive surgical margins in patients with organ-confined prostate cancer results in biochemical recurrence at a similar rate to that in patients with extracapsular extension and PSA ≤ 10 ng/ml.
O. Eminaga (2014)
Seoul National University Prostate Cancer Stage Calculator: Generalization and Head-to-Head Comparison with 2013 Partin Table by Multicenter Cohort
C. Jeong (2013)
10.1016/s1569-9056(18)32049-9
The benefits and harms of different extents of lymph node dissection during radical prostatectomy for prostate cancer: A systematic review
N. Fossati (2018)
10.5152/TUD.2016.52893
Is extended pelvic lymph node dissection for prostate cancer the only recommended option? A systematic over-view of the literature.
Thomas Rees (2016)
10.18632/oncotarget.22459
Prognostic significance of six clinicopathological features for biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis
H. Liu (2018)
10.2147/OTT.S151314
Prognostic value of selected preoperative inflammation-based scores in patients with high-risk localized prostate cancer who underwent radical prostatectomy
K. Shu (2018)
10.1016/j.eururo.2016.12.003
The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review.
N. Fossati (2017)
Effect of Gleason scores of lymph node metastases on prognosis of patients with prostate cancer.
Kyungtae Ko (2014)
10.1111/j.1442-2042.2012.03040.x
Nomograms to predict the pathological stage of clinically localized prostate cancer in Korean men: Comparison with Western predictive tools using decision curve analysis
C. Jeong (2012)
10.1007/978-981-10-6943-7_5
Pelvic Lymphadenectomy for High-Risk Prostate Cancer
C. Lee (2018)
10.20471/ACC.2019.58.S2.05
The Role of Lymphadenectomy in Prostate Cancer Patients
D. Markić (2019)
Factores clínicos y patológicos predictores de recurrencia luego de prostatectomía radical en pacientes con cáncer de próstata de alto riesgo Clinic and pathologic risk factors of recurrence after radical prostatectomy in high-risk prostate cancer patients
R. Bengió (2013)
10.1159/000497280
Reconsideration on Clinical Benefit of Pelvic Lymph Node Dissection during Radical Prostatectomy for Clinically Localized Prostate Cancer
N. Fujimoto (2019)
Semantic Scholar Logo Some data provided by SemanticScholar